case_images: PMC7183339_01
case_images: H&E staining of postoperative tumor sample indicating PSCC, PD-L1 staining of tumor sample, negative control and positive control by Ventana SP263 PD-L1 staining kit. Tumor sample was PD-L1 positive (>=10%).
case_images: OTT-13-3319-g0001.jpg
case_images: PMC7183339_01_OTT-13-3319-g0001.jpg
case_images: F0001
case_images: Postoperative pathological results indicated PSCC (Figure 1). SRA accession: PRJNA612189. Results indicated positive PD-L1 expression (>=10%) (Figure 1), microsatellite stable (MSS), and a tumor mutation burden (TMB) of 8.87 (Muts/Mb). Several mutations were found: PIK3CA p.G106V, CDKN2A p.R80*, TERT c.-124C>T and
case_images: CT. result of tumor lesions in lung and lymph nodes before, or after 2 months, 6 months and 10 months of immunotherapy as indicated by arrows. Lesions continued recessing.
case_images: OTT-13-3319-g0002.jpg
case_images: PMC7183339_01_OTT-13-3319-g0002.jpg
case_images: F0002
case_images: Partial response was soon observed on April 15, 2019 and confirmed on June 5, 2019 by CT (Figure 2). To the date of submission, the patient reached a PFS exceeding 6 months since immunotherapy (Figure 2), and lesions were still under control by January 2020 whereas the PFS exceeded 10.5 months.
case_images: Schematic picture showing the time line of treatment procedure.
case_images: OTT-13-3319-g0003.jpg
case_images: PMC7183339_01_OTT-13-3319-g0003.jpg
case_images: F0003
case_images: Unfortunately, multiple small pulmonary nodules were observed by enhanced CT in both lungs soon afterwards, indicating metastasis and disease progression (Figure 3). The patient was still alive and under treatment (Figure 3).